Investigating the role of leukemia stem cells in acute myeloid leukemia
Official title: Functional Interrogation of Human Acute Myeloid Leukemia Stem Cells
Funded at Stanford University · NIH-11045165 · Data updated 2026-11-12
This study is looking at the tiny cells that help leukemia grow, using special tools to see how changes in their genes affect the disease, with the hope of finding better treatments for people with acute myeloid leukemia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $439,644 |
| NIH project number | 1R01CA288731-01A1 |
| Project ID | NIH-11045165 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with acute myeloid leukemia, particularly those with specific genetic mutations.
✕Less likely to help
Patients with other types of leukemia or those who are not diagnosed with acute myeloid leukemia may not benefit from this research.
What this research studies
This research focuses on understanding the biology of leukemia stem cells (LSCs) in acute myeloid leukemia (AML) using advanced techniques like CRISPR/Cas9 for genome editing. By studying how specific mutations affect the behavior and frequency of these stem cells, the research aims to uncover insights into disease initiation and maintenance. The team will also create induced pluripotent stem cells (iPSCs) from AML samples to explore their potential for developing new treatments. This approach could lead to a better understanding of AML and improved therapeutic strategies for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for acute myeloid leukemia by targeting the underlying stem cell mechanisms.
How similar studies have gone: Previous research has shown promise in using similar genetic engineering techniques to study cancer stem cells, indicating potential for success in this area.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Majeti, Ravindra — Stanford University
- Study coordinator: Majeti, Ravindra
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.